Of note, the only two patients with DH-DJH recombination without accompanying VH-DJH recombination were assigned to the rare molecular subtype CDX2/UBTF, a novel BCP-ALL subgroup with the need of intensified treatment that was identified in 7% of our cohort (26) (see below). Here, CDX2 is linked to acute lymphoblastic leukemia.